MacroArray Diagnostics GmbH
Allergies and asthma affect one at least a quarter of the population. While often harmless, an increasing number of people suffer from severe allergies, resulting in more than 30.000 avoidable deaths per year. Presently, there is no cost-efficient technology to improve the quality of diagnosis to an optimal level for patient-tailored and evidence based treatment. The consequences of technology lagging knowledge are: generally elevated disease management costs, reduced quality of life and avoidable deaths. We develop a multi-parameter allergy test covering close to 100% of the globally relevant allergens in a single lab test. Thereby we eliminate the trade-off between cost and quality of diagnosis. We combine traditional allergenic extract-based testing with contemporary molecular allergy diagnosis, explained by intelligent reporting tools. Our product will be directly and indirectly cost-effective. We offer a one-stop-shop and right-first-time test that has the potential to change the routine of allergy diagnosis. While currently in-vitro tests are conducted as second or third step in the diagnostic proceedings, we envision that comprehensive, high-resolution yet sensitive screening tests must become a first level tool, only to be followed up by confirmatory anamnesis, skin tests or provocation. The benefits will serve the entire value chain, but most importantly allergic patients.
Project CMV plans to develop a first-in-class drug for the treatment of viral infections. The molecule acts by inhibiting a molecule important for the viral life-cycle. It has shown to be efficacious in cell and animal models including CMV, Ebola virus, HIV and Rift Valley Fever virus. The primary indication for PCMV-01 will be CMV-break-through infection in solid-organ transplant (SOT) patients for which we expect an orphan designation. Currently approved drugs are highly toxic and many SOT patients develop CMV break-through disease with potentially fatal consequences for the transplant and the patient. New drugs are urgently needed because of the substantial side effect profiles of existing drugs and the increasing occurrence of drug-resistant viruses. Our data suggests that PCMV-01 will have a moderate side-effect and toxicity profile, yet, a superior anti-viral activity. The team covers all relevant areas of expertise including science, venture creation and financing of startups.
The objective of ImageBiopsy Lab (IB Lab GmbH) is to provide the tools for an effective treatment of knee-osteoarthritis. So far, osteoarthritis progression is considered to be hardly stoppable. Our software solution will change this. IB Lab simplifies and accelerates the assessment, follow-up and prediction of knee osteoarthritis. Different stages of osteoarthritis and their accompanying symptoms are thus measured objectively and with minimal effort. An early prediction is possible for the first time without additional imaging efforts. The time-to-result is reduced from up to 3 minutes to a few seconds. This means a significant relief for the medical professional in the daily routine. In addition, clearly defined treatment paths can be initiated on the basis of objectively measured parameters, resulting in an effective treatment of osteoarthritis progression.
decide Clinical Software GmbH
Our GlucoTab® system provides support for professionals involved in the insulin therapy of patients with Type 2 Diabetes on hospital wards. The system improves blood glucose management and suggests correct insulin dosages. (CDSS)
The features are:
- Standardization of processes
- Quality: Measurements are performed and appropriate action is taken
- Efficiency: Reduction in staff workload due to standardized procedures
- Cost reduction: Reduction of complications is achievable in a cost-effective way
- Clinical decision support (CDSS) Due to the suggested dosages calculated by the system and the up-to-date overview of completed and open tasks, there is less pressure on medical staff and errors a significantly reduced.
- Improving blood glucose Control. Our Clinical studies confirmed that average blood glucose concentration was reduced by 20% compared to standard care.
Lower blood glucose leads to lower rate of patient complications! No one else in Europe can deliver such a CDSS in Europe today!
BHS was found in February 2017 to develop a disruptive medical device, which will enhance the performance of microsurgical procedures for all participants - patient, surgeon and hospital. After a successful demonstration of the concept, the team has started to develop the product for clinical use.
UriSalt is a company developing Point-of-Care Tests for assessing body electrolyte status. Electrolyte imbalance can be quite detrimental to human health. Each electrolyte serves a specific and important role, their balance is critically important for functions like hydration, nerve impulses, muscle contraction/relaxation and pH level.
SODISENS is the first product of UriSalt developed to provide immediate and reliable information on body sodium (Na) status from urine. It is an easy to handle, inexpensive PoCT that can be performed at any time by medical personnel and/or by the patient him-/herself. Disorders of body Na status affect up to two billion subjects worldwide. At present, Na-status is assessed invasively from blood plasma. An easy-to-perform on-site test such as SODISENS allows patients highest mobility, while reducing the risk of severe complications that may result from Na-balance disorders. For the health care system, this means reduced number of patient visits and costs.
contextflow develops deep learning methods to analyze big medical data and identify clinically relevant structures in medical images. Our technology allows radiologists to mark a region of interest containing a pathological appearance in a medical image (e.g. CT or MRI) and within seconds finds visually similar cases, including their descriptions. This way radiologists, for the first time, can efficiently browse through the PetaBytes of existing medical image data, and also get easy access to case relevant reference information, online literature, and relevant differential diagnosis. We bring case relevant information closer to the point of care and support radiologists so that they can focus on diagnosing their patient images instead of wasting valuable time searching for information. In addition, the system has the potential to learn, identify novel biomarkers in the complexity of big medical data.
MorphoMed GmbH (founded 2.5.2017) is a Vienna-based medical technology start-up company, specializing in the development and commercialization of Class III medical products for regenerating endogenous natural tissue (e.g. ligaments or tendons) using proprietary protected medical silk manufacturing technology. MorphoMed wants to become a sustainable player in the field of regenerative, silk based medicine. The company's lead product is an anterior cruciate ligament made of medical silk (RegACL - "regenerative anterior cruciate ligament"), which has already been successfully tested in studies with large animals (sheep). The development, production, clinical approval, product launch and sales of RegACL will form the technological and commercial basis for building up MorphoMed GmbH and for the development of derived and related silk products. Before becoming cash positive in 2021, financing of EUR 2,9 Million is needed from private equity, public grants and strategic cooperation partners. Commercial success will be driven by the development and market introduction of the lead product RegACL but also by a strong pipeline of related products based on the silk manufacturing technology.
NP Life Science Technologies KG
NP Life Science Technologies KG develops and produces an implantable biodegradable scaffold that supports the regeneration of damaged, dissected, cut peripheral nerves. It has a length of several millimetres and consists of numerous parallel aligned microchannels with a diameter of a 100-200 µm. Thus, the scaffold resembles the extracellular matrix of a nerve. It gives immediate growth guidance for micrometre large regenerating nerve cells and protrusion from the proximal to the distal nerve stump. Benefits for patients are a faster regeneration of damaged peripheral nerves due to existing growth guidance, going along with a fast recovery and a sustained quality of life. The health care system and labour market profit by shorter medical after-treatment, faster reintegration in the labour market and less occupational redeployment.
VALANX Biotech GmbH
Site-specific protein conjugation represents a significant challenge in products of biotechnology like conjugated therapeutics (Antibody-Drug-Conjugates, PEGylated therapeutics, conjugated vaccines), biosensors and biocatalysts. We have developed a biocatalytic one-pot production process for a synthetic reactive amino acid from cheaply available industrial chemicals. The amino acid carries a reactive group that is used to make chemical connections to the protein. We develop prokaryotic and mammalian expression systems that enable us to incorporate this amino acid in a site-specific way into proteins. This way we enable the production of protein conjugates at a 50-fold reduced price point than our closest competitor. Our technology can be applied to all protein products. We focus on the development of conjugated therapeutics and aim for partnering developments with established pharmaceutical companies.